NCT00095758 - A Study of Adjunctive Aripiprazole in Patients With Major Depressive Disorder | Biotech Hunter

Enrollment

1,200

Participants

Timeline

Start Date

September 30, 2004

Primary Completion Date

December 31, 2006

Study Completion Date

December 31, 2006

Conditions

Major Depressive Disorder

Interventions

DRUG

Antidepressant + Placebo

Antidepressant Caps/Tablets Placebo Tablets, Oral, 2-20 mg Placebo, once daily, 6 weeks following an 8 week Prospective Treatment (Baseline) Phase.

DRUG

Antidepressant + Aripiprazole

Antidepressant Caps/Tablets Aripiprazole Tablets, Oral, 2-20 mg Aripiprazole, once daily, 6 weeks following an 8 week Prospective Treatment (Baseline) Phase.

Trial Locations (28)

Unknown

Local Institution, Beverly Hills

Local Institution, Burbank

Local Institution, National City

Local Institution, Orange

Local Institution, Pasadena

Local Institution, Denver

Local Institution, Farmington

Local Institution, Jacksonville

Local Institution, Orlando

Local Institution, Atlanta

Local Institution, Rockville

Local Institution, Albuquerque

Local Institution, Brooklyn

Local Institution, New York

Local Institution, Cincinnati

Local Institution, Toledo

Local Institution, Portland

Local Institution, Pittsburgh

Local Institution, Memphis

Local Institution, Dallas

Local Institution, Houston

Local Institution, Arlington

Local Institution, Herndon

Local Institution, Richmond

Local Institution, Bellevue

Local Institution, Seattle

Local Institution, Brown Deer

Local Institution, Middleton